
|Articles|September 3, 2013
Mechanism of Action: Antibody-Drug Conjugates
Despite recent oncology breakthroughs, conventional anticancer treatments may have limitations. Decades of research are resulting in the capacity to create a new generation of antibody drug conjugates.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5








































